153 related articles for article (PubMed ID: 2724674)
1. Preventive effect of MK-733 (simvastatin), an inhibitor of HMG-CoA reductase, on hypercholesterolemia and atherosclerosis induced by cholesterol feeding in rabbits.
Kobayashi M; Ishida F; Takahashi T; Taguchi K; Watanabe K; Ohmura I; Kamei T
Jpn J Pharmacol; 1989 Jan; 49(1):125-33. PubMed ID: 2724674
[TBL] [Abstract][Full Text] [Related]
2. Comparative effects of simvastatin (MK-733) and pravastatin (CS-514) on hypercholesterolemia induced by cholesterol feeding in rabbits.
Ishida F; Watanabe K; Sato A; Taguchi K; Kakubari K; Kitani K; Kamei T
Biochim Biophys Acta; 1990 Feb; 1042(3):365-73. PubMed ID: 2106347
[TBL] [Abstract][Full Text] [Related]
3. [Preventive effect of simvastatin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on coronary atherosclerosis in cholesterol-fed rabbits].
Oogushi K
Fukuoka Igaku Zasshi; 1991 Feb; 82(2):36-47. PubMed ID: 2022360
[TBL] [Abstract][Full Text] [Related]
4. [Simvastatin (MK-733), a new HMG-CoA reductase inhibitor, in the treatment of hypercholesterolemia in elderly patients with atherosclerosis].
Giannini SD; de Góes JM; Dereviack BE; Machado C; Forti N; Diament J
Arq Bras Cardiol; 1990 Jun; 54(6):407-14. PubMed ID: 2288531
[TBL] [Abstract][Full Text] [Related]
5. Low-dose effect of simvastatin (MK-733) on serum lipids, lipoproteins, and apolipoproteins in patients with hypercholesterolemia.
Saku K; Sasaki J; Arakawa K
Clin Ther; 1989; 11(2):247-57. PubMed ID: 2736571
[TBL] [Abstract][Full Text] [Related]
6. Effects of MK-733 (simvastatin), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on intestinal acylcoenzyme A:cholesterol acyltransferase activity in rabbits.
Ishida F; Sato A; Iizuka Y; Kitani K; Sawasaki Y; Kamei T
Biochim Biophys Acta; 1989 Jul; 1004(1):117-23. PubMed ID: 2742865
[TBL] [Abstract][Full Text] [Related]
7. Effect of simvastatin (MK-733) on sterol and bile acid excretion in rabbits.
Ishida F; Iizuka Y; Kakubari K; Kurahashi Y; Sawasaki Y; Kamei T
Jpn J Pharmacol; 1990 May; 53(1):35-45. PubMed ID: 2352377
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
9. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models.
Krause BR; Newton RS
Atherosclerosis; 1995 Oct; 117(2):237-44. PubMed ID: 8801869
[TBL] [Abstract][Full Text] [Related]
10. Effects of MK-733, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, on absorption and excretion of [3H]cholesterol in rabbits.
Ishida F; Sato A; Iizuka Y; Sawasaki Y; Aizawa A; Kamei T
Biochim Biophys Acta; 1988 Nov; 963(1):35-41. PubMed ID: 3179328
[TBL] [Abstract][Full Text] [Related]
11. The use of simvastatin, an HMG CoA reductase inhibitor, in older patients with hypercholesterolemia and atherosclerosis.
Bach LA; Cooper ME; O'Brien RC; Jerums G
J Am Geriatr Soc; 1990 Jan; 38(1):10-4. PubMed ID: 2404052
[TBL] [Abstract][Full Text] [Related]
12. Effect of simvastatin (MK-733) on the regulation of cholesterol synthesis in Hep G2 cells.
Nagata Y; Hidaka Y; Ishida F; Kamei T
Biochem Pharmacol; 1990 Aug; 40(4):843-50. PubMed ID: 2167097
[TBL] [Abstract][Full Text] [Related]
13. Simvastatin further enhances the hypocholesterolemic effect of soy protein in rabbits.
Giroux I; Lavigne C; Moorjani S; Jacques H
J Am Coll Nutr; 1997 Apr; 16(2):166-74. PubMed ID: 9100218
[TBL] [Abstract][Full Text] [Related]
14. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW
Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
[TBL] [Abstract][Full Text] [Related]
15. Effects of long-term treatment with simvastatin on plasma lipids and lipoproteins in patients with primary hypercholesterolemia.
Thiery J; Creutzfeldt C; Creutzfeldt W; Walli AK; Seidel D
Klin Wochenschr; 1990 Aug; 68(16):814-22. PubMed ID: 2214604
[TBL] [Abstract][Full Text] [Related]
16. Simvastatin inhibits myointimal hyperplasia following carotid artery injury in cholesterol-fed rabbits.
Dol F; Mares A; Herbert J
Blood Coagul Fibrinolysis; 1996 Nov; 7(8):772-8. PubMed ID: 9034557
[TBL] [Abstract][Full Text] [Related]
17. Effect of lovastatin on cholesterol absorption in cholesterol-fed rabbits.
Nielsen LB; Stender S; Kjeldsen K
Pharmacol Toxicol; 1993 Mar; 72(3):148-51. PubMed ID: 8516264
[TBL] [Abstract][Full Text] [Related]
18. [Effects of simvastatin on plasma lipids, lipoproteins and apoproteins (A1 and B). 24 cases of major primary hypercholesterolemia].
Aubert I; Emmerich J; Charpak Y; Chanu B; Dachet C; Herlich D; Besseau M; Rouffy J; Jacotot B
Presse Med; 1988 May; 17(18):901-4. PubMed ID: 2968595
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative.
Slater EE; MacDonald JS
Drugs; 1988; 36 Suppl 3():72-82. PubMed ID: 3076125
[TBL] [Abstract][Full Text] [Related]
20. Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.
Cohen LH; van Vliet A; Roodenburg L; Jansen LM; Griffioen M
Biochem Pharmacol; 1993 Jun; 45(11):2203-8. PubMed ID: 8517861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
